News | December 06, 2010

Data Shows New Stent Offers Better Outcomes Over Bare Metal Stents

December 6, 2010 – A new stent shows favorable outcomes compared to bare metal stents (BMS) for treating coronary artery bifurcation lesions. Data for the Genous Stent, from OrbusNeich, was published online in the journal, Atherosclerosis.

The study's primary endpoint, the composite of cardiac death, myocardial infarction (MI) or target lesion revascularization (TLR) at one year, was 12.4 percent in patients treated with a Genous Stent, compared to 17.2 percent for the control group treated with BMS. The definite or probable stent thrombosis (ST) rate was 1.7 percent for the Genous Stent patient group, compared to 3.4 percent for the BMS treated patient group.

"Interventional cardiologists continue to be challenged by the 15 to 20 percent of all percutaneous coronary interventions that involve coronary artery bifurcation lesions," said Marcel Beijk, M.D., of the Academic Medical Center in Amsterdam, the lead author of the paper. "The results of this large study of provisional T-stenting using the Genous Stent are extremely encouraging. The endothelial progenitor cell capture stent provides an excellent alternative to bare metal stents for the treatment of these challenging lesions."

The paper is based on a single-center, non-randomized study. The study involved 178 patients who underwent percutaneous coronary intervention for a de novo bifurcation lesion treated with a Genous Stent and 465 consecutive patients treated with BMS.

The Genous Stent uses the company’s endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after stent implantation. An antibody surface coating attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

For more information: www.OrbusNeich.com

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init